There were significant updates and restructuring of the guidelines, with some highlights included below:
- Substantial reorganization of the guidelines as follows:
- Now organized by organ site, rather than primarily by certain high penetrance genes
- Focused efforts to simplify genetic testing criteria
- Only one flow diagram included, to outline the ‘genetic testing process’
- Following scenarios now outlined:
- Situations in which genetic testing may have low yield
- Situations where referral to a genetics expert is recommended
- PALB2: Recognized as a high penetrance gene, for which discussion of risk-reducing mastectomy is appropriate
- BRCA1/2: Prostate cancer screening to be initiated at age 40
- Pancreatic screening guidance included:
- STK11 starting at age 30-35
- CDKN2A starting at age 40
- BRCA1/2, ATM, MLH1, MSH2, MSH6, EPCAM, PALB2, or TP53: Only if there is a close family member with pancreatic cancer
For the complete updated versions of the NCCN guidelines, please visit NCCN.org
Follow this link to view our social media post: https://tinyurl.com/ICARE2019124
Full press release available at: https://www.nccn.org/about/news/newsinfo.aspx?NewsID=1790